Navigation Links
Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
Date:10/2/2013

ndo con las restantes actividades de solicitud de nuevo fármaco".

La prueba clínica EASED™ Fase 2/3 se creó para investigar la seguridad y la eficacia de tres niveles de dosis de ADS-5102 administradas una vez por la noche, a la hora de acostarse, para el tratamiento de la LID en la PD. En el estudio participaron 83 sujetos que fueron aleatorizados en una relación de 1:1:1:1 para los cuatro grupos de tratamiento: placebo, 260 mg de ADS-5102, 340 mg de ADS-5102 y 420 mg de ADS-5102. Tanto el nivel de dosis de 340 mg como el de 420 mg de ADS-5102 redujeron considerablemente la LID medida por el cambio en la puntuación total de la Escala Unificada para la Evaluación de la Disquinesia (UDysRS) en ocho semanas frente al placebo, alcanzando el punto final primario del estudio clínico. Es de notar que la reducción en la LID se vio a las dos semanas después de la primera dosis de medicamento en el estudio. En la octava semana, el período de respuesta a los medicamentos sin disquinesia molesta, medido por los diarios de los pacientes, fue de 11.0 horas, 11.5 horas y 12.1 horas para los niveles de dosis de 260 mg, 340 mg y 420 mg, respectivamente, en comparación con 8.0 horas para el placebo. Estos resultados fueron estadísticamente significativos, demostrando un incremento de unas 3 horas sobre el placebo en comparación con los valores de la línea de base.  ADS-5102 también mostró una mejora funcional estadísticamente significativa en la disquinesia evaluada según la parte IV de la MDS-Escala Unificada para la Evaluación de la Enfermedad de Parkinson (MDS-UPDRS), una medida del grado de impacto que la disquinesia tiene en la función diaria del paciente en actividades e interacciones sociales.

El tratamiento con ADS-5102 no dio como resultado un empeoramiento de la PD, según la medición de la puntuación combinada de MDS-UP
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
4. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
8. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
11. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... By Steven Reinberg ... -- Living close to a major highway may raise your ... Among more than 5,000 postmenopausal women, those who lived within ... greater risk of developing high blood pressure than women living ... "The results of this study highlight the importance of our ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... team of scientists has shown that more than 80 ... existing drugs. , The study found that medicines called ... a genetic mutation that is present in more than ... are currently used, or are in clinical trials, for ... disorders. , Bowel cancer is the second-most common cancer ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... Nov. 19 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... as senior vice president, operations. "We are ... and,supply chain management to our already strong senior ... and chief operating,officer. Ms. Ellerbrock, 46, joins ...
... up on a study that found widespread failures in ... team from the Johns Hopkins Childrens Center and Duke ... more than a mock trauma drill to diagnose the ... sharp again. Their report appears in the November issue ...
... rose , , MONDAY, Nov. 19 (HealthDay News) -- A new ... on the body, which may explain why people of lower ... report. , The link between higher levels of inflammatory molecules ... by poor diet and lack of exercise, the study suggests. ...
... are adding to the obesity crisis its fruit drinks, ... of North Carolina at Chapel Hill School of Public Health ... cider are abundant, the problem can be even more apparent. ... adults get through beverages has nearly doubled, according to a ...
... PHILADELPHIA According to a study that appears in ... Neuroscience), researchers at the University of Pennsylvania School of ... neural responses to psychological stress. , We ... different spatial and temporal profiles for men and women ...
... 2007 Campaign highlighted by new partnership with the NFL ... Romano, Antonio Banderas, New Orleans Saints, Reggie Bush and Marlo ... will also launch in ... Jude Children,s Research Hospital,has launched its 2007 Thanks and Giving ...
Cached Medicine News:Health News:Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 3Health News:Researchers Spot Link Between Heart Disease, Income 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 3Health News:Penn researchers use brain imaging to demonstrate how men and women cope differently under stress 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 3Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 4Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 5Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 6
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: